Haleon Is Just One Of 3 British AI Healthcare Stocks

AI spending is under the spotlight after large US tech groups flagged heavy investment, and that same surge in interest is spilling into how healthcare is funded and delivered in Britain. Investors looking for exposure to this shift are starting to pay closer attention to UK companies using algorithms to support diagnosis and treatment. This article picks out three AI driven healthcare stocks from our screener that are worth having on your radar.

The three stocks highlighted below are just a sample of what this theme throws up, as the full screen surfaced 5 more AI driven healthcare companies with equally compelling narratives that are not covered in this article. To go wider than these examples, identify fresh ideas, and analyze which opportunities fit your own criteria best, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Haleon (LSE:HLN)

Haleon brings AI into everyday healthcare through its Microsoft partnership, using data tools to sharpen how it designs, markets, and supplies well known consumer brands across North America, EMEA and Latam, and Asia Pacific, where it generated £3.8b, £4.7b, and £2.6b of revenue respectively. The group is valued at about £33.6b.

For investors tracking how AI is reshaping healthcare, Haleon offers a different angle, applying data driven tools to a large self care portfolio rather than hospital systems or drug pipelines. This makes the next piece of its AI story especially important.

"Extending the current productivity and AI programme, which has already delivered 140 basis points of gross margin improvement alongside SKU and formulation reduction, provides room for further structural cost savings that could widen net margins and raise free cash flow beyond what is implied by modest top line growth."

What happens to that potential depends heavily on one unresolved pressure point that could either quietly cap or significantly lift those future margin gains.

If that pressure point is on your mind, the full narrative for Haleon explains how margin ambition, AI spend and brand firepower could be pulling in different directions.

Abingdon Health (AIM:ABDX)

Abingdon Health taps into AI driven diagnostics through its Appdx smartphone reader and broader lateral flow services. Most income still comes from contract development at about £5 million and regulatory work at about £4.1 million, with a market value near £39 million.

Abingdon Health gives you exposure to AI powered testing at the smartphone level, where software turns simple strips into data rich, remotely managed diagnostics that fit directly with this screener’s focus on more accurate and accessible healthcare.

"Broader adoption of rapid point of care and self testing across multiple therapy areas is creating more demand for lateral flow based companion diagnostics."

What happens if one emerging constraint quietly limits how far those smartphone linked tests can scale into higher margin, longer contract work?

That emerging constraint is the real swing factor, and the full narrative for Abingdon Health explains how it could reframe Abingdon Health, shifting the company’s position from niche contractor into an accelerating platform play.

AstraZeneca (LSE:AZN)

AstraZeneca is a global biopharmaceutical group developing prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and rare diseases, while using AI partnerships in oncology to sharpen drug discovery. The business generated about US$61.4b from pharmaceuticals and carries a market value near £198.9b.

AstraZeneca pushes deeper into AI driven healthcare through oncology partnerships that try to fuse imaging, genomic and clinical data. This matters for this screener because it could reshape how quickly complex cancer medicines move from lab concept to real world treatment.

"Large scale investments in AI enabled discovery and a multi billion dollar capital build out, including a new ADC facility and expanded emerging market manufacturing, increase fixed costs. If AI and digitization do not translate into faster approvals or better pipeline success, the combination of R&D at roughly 23% of revenue and higher depreciation could pressure earnings and free cash flow."

What happens if one less visible turning point in that AI heavy oncology push quietly changes how much operating leverage actually reaches AstraZeneca’s bottom line?

That inflection point is exactly what the full narrative for AstraZeneca unpacks, revealing where AstraZeneca’s AI spend could quietly start accelerating returns instead of just inflating fixed costs.

Seeking Alternatives Before Momentum Flies Past

Fresh opportunities move fast, and the best setups rarely stay under the radar for long. Scan these focused stock lists before the breakout momentum is caught, and consider your options in a timely way.

• Tap into lower priced shares with real balance sheet strength by running the 15 elite penny stocks with strong financials before the crowd starts chasing the next wave of momentum.
• Target dependable income ideas by scanning the 5 dividend fortresses while yields remain elevated and prices have not fully reflected that payout profile yet.
• Hunt for potential future leaders hiding in plain sight by reviewing the 5 high quality undiscovered gems while these stories are still under the radar for now.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com